Moleculin Biotech Enrolls 45th Participant In Its Pivotal Phase 2B/3 MIRACLE Study Of Annamycin In Combination With Cytarabine To Treat Relapsed Or Refractory Acute Myeloid Leukemia

뉴스 본문을 불러오고 있어요.

Moleculin Biotech Enrolls 45th Participant In Its Pivotal Phase 2B/3 MIRACLE Study Of Annamycin In Combination With Cytarabine To Treat Relapsed Or Refractory Acute Myeloid Leukemia | 웨이프 WAPE

Moleculin Biotech Enrolls 45th Participant In Its Pivotal Phase 2B/3 MIRACLE Study Of Annamycin In Combination With Cytarabine To Treat Relapsed Or Refractory Acute Myeloid Leukemia

기사 요약

관련 종목

댓글 —